Holen Sie sich die Stockscreener-App
55.31
1.60%
0.87
Handel nachbörslich:
55.31
Schlusskurs vom Vortag:
$54.44
Offen:
$54.93
24-Stunden-Volumen:
650.86K
Relative Volume:
0.73
Marktkapitalisierung:
$5.80B
Einnahmen:
$628.56M
Nettoeinkommen (Verlust:
$141.82M
KGV:
43.90
EPS:
1.26
Netto-Cashflow:
$142.60M
1W Leistung:
+10.95%
1M Leistung:
+0.31%
6M Leistung:
+66.40%
1J Leistung:
+122.84%
1-Tages-Spanne:
$53.76
$55.36
1-Wochen-Bereich:
$49.00
$55.36
52-Wochen-Spanne:
$20.84
$62.22
Corcept Therapeutics Inc Stock (CORT) Company Profile
Firmenname
Corcept Therapeutics Inc
Sektor
Branche
Telefon
650.688.8803
Adresse
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Vergleichen Sie CORT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
55.31 | 5.80B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-06 | Hochstufung | Truist | Hold → Buy |
| 2023-04-11 | Eingeleitet | SVB Securities | Market Perform |
| 2023-04-04 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-15 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-01 | Herabstufung | Truist | Buy → Hold |
| 2022-07-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-06-27 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-01-28 | Eingeleitet | Truist | Buy |
| 2020-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2019-09-24 | Eingeleitet | Jefferies | Buy |
| 2019-09-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-02-04 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | Bestätigt | Stifel | Hold |
| 2018-05-31 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-09 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | Eingeleitet | Stifel | Buy |
| 2017-02-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2015-04-21 | Eingeleitet | FBR Capital | Outperform |
| 2014-01-13 | Herabstufung | Stifel | Buy → Hold |
| 2013-08-09 | Herabstufung | Janney | Buy → Neutral |
| 2013-08-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | Bestätigt | JMP Securities | Mkt Outperform |
| 2010-01-06 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | Hochstufung | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Alle ansehen
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
Here’s Why Analysts Are Bullish on Corcept Therapeutics Incorporated (CORT) - Insider Monkey
Ovarian Cancer Drugs Market Analysis: Segments, Drivers, - openPR
Here's What Could Help Corcept (CORT) Maintain Its Recent Price Strength - MSN
Corcept Therapeutics Incorporated (CORT): Why Should You Buy This Growth Stock For The Next 5 Years? - Yahoo Finance
Hennion & Walsh Asset Management Inc. Trims Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Burney Co. Increases Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Sells $111,188.00 in Stock - MarketBeat
Corcept Therapeutics director Daniel Swisher sells $111,188 in stock By Investing.com - Investing.com Canada
Corcept Submits Application for Another Cushing's Syndrome Drug - MSN
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Cushings Syndrome Market Is Booming Worldwide 2024-2031 | Corcept Therapeutics Inc., HRA Pharma - EIN News
Range Financial Group LLC Buys New Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Incorporated (CORT) Surged on Strong Results and Increased Guidance - Yahoo Finance
Corcept Therapeutics officer sells shares for $251,950 - Investing.com India
Corcept Therapeutics officer sells shares for $251,950 By Investing.com - Investing.com Australia
Sean Maduck Sells 20,000 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock - MarketBeat
Corcept Therapeutics' chief business officer sells shares worth $555,551 By Investing.com - Investing.com Nigeria
Corcept Therapeutics' chief business officer sells shares worth $555,551 - Investing.com
Corcept Therapeutics president sells $1 million in stock By Investing.com - Investing.com Canada
Corcept asks FDA to OK relacorilant for Cushing’s syndrome - Cushing's Disease News
Analysts Set Corcept Therapeutics Incorporated (NASDAQ:CORT) Target Price at $65.25 - MarketBeat
Here's Why Corcept Therapeutics (NASDAQ:CORT) Has Caught The Eye Of Investors - Simply Wall St
Corcept files NDA for new Cushing's syndrome drug By Investing.com - Investing.com Canada
Corcept Therapeutics Submits New Drug Application for Cushing's Sydrome Treatment - MarketWatch
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism - Business Wire
Corcept Therapeutics Submits FDA Application for Breakthrough Cushing's Syndrome Treatment Relacorilant - StockTitan
Principal Financial Group Inc. Lowers Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Will Corcept Therapeutics Incorporated (CORT) Make You Rich In 2025? - Yahoo Finance
10 Stocks That Will Make You Rich In 2025 - Insider Monkey
Hypercortisolism research fuels Corcept’s DTC awareness campaign - MM+M Online
What is Zacks Research's Forecast for CORT FY2025 Earnings? - MarketBeat
Abortion Drugs Market Growth in Future Scope 2024-2031 | Corcept - openPR
Zacks Research Issues Negative Forecast for CORT Earnings - MarketBeat
Geode Capital Management LLC Grows Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
World Investment Advisors LLC Takes Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept’s dazucorilant fails to slow ALS progression in clinical trial - ALS News Today
Corcept Therapeutics’ Cushing’s syndrome therapy shows promise in Phase III trial - Yahoo Finance
Corcept Therapeutics Incorporated (NASDAQ:CORT) Short Interest Down 7.0% in November - MarketBeat
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism - BioSpace
Relacorilant shows promise in long-term hypercortisolism study - Investing.com
Corcept's Phase 3 Study Shows Breakthrough Blood Pressure Results for Relacorilant in Long-term Treatment - StockTitan
Stifel Financial Corp Buys 20,546 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Shares Rise More Than 60% in Three Months: Here's Why - MSN
State Street Corp Has $162.87 Million Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study - MSN
Community Spotlight: Breakthrough Type 1 Diabetes Walk - AOL
Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes - Yahoo Finance
Korlym shows promise in Cushing's syndrome study By Investing.com - Investing.com Canada
Verition Fund Management LLC Sells 28,931 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes - BioSpace
Corcept Therapeutics Diabetes Drug Korlym Meets Primary Endpoint in Study - MarketWatch
Finanzdaten der Corcept Therapeutics Inc-Aktie (CORT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
4.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):